1. A method of treating a tumor disease in a human subject, comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an anti-L-1α antibody effective for treating a tumor disease. The method of claim 1, wherein the anti-IL-1α antibody is a monoclonal antibody. The method of claim 2, wherein the monoclonal antibody is IgGl. 4. The method of claim 2, wherein the monoclonal antibody comprises a hypervariable region from MABp1.5. The method of claim 2, wherein the monoclonal antibody is MABp1.6. The method of claim 1, wherein the tumor disease is a colorectal tumor disease. The method of claim 1, wherein the tumor disease is a KRAS mutated tumor disease. The method of claim 1, wherein the tumor disease is associated with EBV infection. The method of claim 1, wherein the tumor is a nasopharyngeal carcinoma. The method of claim 1, wherein the tumor disease is lung cancer. The method of claim 1, wherein the tumor disease is a non-cancerous condition associated with neoplasms of blood cells. The method of claim 1, wherein the tumor disease is Castelman disease. A method of reducing the size of a tumor in a human subject, comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of anti-IL-1α antibody, effective to reduce the size of the tumor in the subject. A method for reducing edema in a human subject, comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an anti-IL-1α antibody effective to reduce edema in the subject. A way to reduce neuropathy1. Способ лечения опухолевого заболевания у субъекта-человека, включающий этап введения субъекту фармацевтической композиции, включающей фармацевтически приемлемый носитель и количество антитела к L-1α, эффективное для лечения опухолевого заболевания.2. Способ по п.1,
